Highlights from the 56th Annual Scientific Sessions of the American College of Cardiology: March 25 to 27, 2007, Atlanta, Georgia

• Published in: The American heart journal 2007-08, Vol.154 (2), p.247-259
• Main Authors: Adams, George L., MD, Mills, James S., MD, Melloni, Chiara, MD, Allen, Larry A., MD, Jolicoeur, E. Marc, MD, Wang, Tracy, MD, Chan, Mark, MD, Majidi, Mohamed, MD, Lopes, Renato D., MD, PhD
• Format: Article
• Language: English
• Subjects: Cardiology; Cardiovascular; Cardiovascular Diseases - therapy; Clinical Trials as Topic; Coronary vessels; Heart attacks; Humans; Mortality; Older people; Stents
• ISSN: 0002-8703; 1097-6744
• DOI: 10.1016/j.ahj.2007.05.005

Session Late-Breaking Clinical Trials I2 Study: Contemporary results of post market studies EXACT interim analysis Presenter: William A Gray, MD, Columbia University Medical Center, New York, NY Background: Approximately 10% of patients presenting with stroke have underlying carotid stenosis.1 The primary mechanism of stroke in such patients is embolism of atherosclerotic debris or thrombotic material from the plaque into the distal cerebral vasculature.2 Transfemoral carotid artery stenting (CAS) has emerged as a potential alternative to endarterectomy for carotid artery stenosis in terms of both safety and efficacy.3 Many carotid stent systems have been conditionally approved by the Food and Drug Administration following a requirement to monitor for adverse events and track the dissemination of these technologies. The enrollment and follow-up continues for the EXACT (128 sites) and CAPTURE 2 (195 sites) studies. [...]far, the EXACT and CAPTURE 2 studies have evaluated postmarketing data on 1500 and 600 patients, respectively. Six-month angiographic and IVUS results from this first-in-man evaluation of a fully bioabsorbable everolimus-eluting coronary stent Presenter: Patrick W. Serruys, MD, PhD, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands Background and Methods: The development and use of drug-eluting stents during percutaneous coronary intervention has significantly reduced the risk of in-stent restenosis and need for repeat revascularization procedures compared with bare metal stents.1,2 However, the development of a fully bioabsorbable drug-eluting stent may hold several theoretical advantages because a permanent metallic stent may impair normal vascular endothelial function and prevent positive remodeling.